CareDx Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
CDNA$80.77-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating activities: | |||
| Net loss | $(190,284) | $(76,613) | $(30,662) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | |||
| Stock-based compensation | 49,086 | 46,553 | 36,081 |
| Asset impairments and write-downs | 1,000 | 840 | 2,437 |
| Depreciation and amortization | 14,386 | 11,595 | 8,797 |
| Amortization of right-of-use assets | 5,438 | 4,412 | 3,088 |
| Unrealized loss on long-term marketable equity securities | — | 1,181 | 1,743 |
| Realized gain on sale of long-term marketable equity securities, net | (284) | — | — |
| Loss on disposal of asset | 44 | — | — |
| Gain on settlement of obligation and recovery of written-off investment | (2,109) | — | — |
| Revaluation of common stock warrant liability to estimated fair value | (10) | (107) | (106) |
| Revaluation of contingent consideration to estimated fair value | 2,677 | 727 | (609) |
| Accretion of discount and amortization of premium on short-term marketable securities, net | (4,927) | 390 | 1,129 |
| Other non-cash items | — | — | (222) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | 16,016 | (6,660) | (24,416) |
| Inventory | 54 | (2,859) | (6,927) |
| Prepaid and other assets | 1,767 | (1,049) | (5,144) |
| Accounts payable | 2,904 | (2,054) | 1,789 |
| Accrued compensation | 2,655 | (9,251) | 7,516 |
| Accrued and other liabilities | 89,608 | 11,327 | 10,690 |
| Accrued royalties | (1,557) | — | — |
| Operating lease liabilities, net | (5,418) | (3,456) | (2,603) |
| Refund liability - CMS advance payment | — | — | (20,496) |
| Change in deferred taxes | 566 | (215) | (1,379) |
| Net cash used in operating activities | (18,388) | (25,239) | (19,294) |
| Investing activities: | |||
| Maturities of short-term marketable securities | 256,038 | 111,587 | 88,905 |
| Purchases of short-term marketable securities | (201,165) | (315,145) | — |
| Purchases of long-term marketable securities | — | — | (5,500) |
| Purchase of corporate equity securities | (965) | — | — |
| Sale of corporate equity securities | 2,460 | — | — |
| Additions of capital expenditures | (8,344) | (21,234) | (13,559) |
| Acquisition of intangible assets | (896) | (3,100) | (6,700) |
| Acquisition of business, net of cash acquired | (6,682) | (610) | (15,434) |
| Net cash provided by (used in) investing activities | 40,446 | (228,502) | 47,712 |
| Financing activities: | |||
| Proceeds from issuance of common shares in public equity offering, net of issuance costs paid | — | — | 188,855 |
| Payment of contingent consideration | (625) | (2,625) | — |
| Principal payments on finance lease obligations | — | — | (66) |
| Repurchase and retirement of common stock | (27,541) | (642) | — |
| Proceeds from exercise of warrants | 4 | — | 4 |
| Proceeds from exercise of stock options | 120 | 2,435 | 12,775 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,495 | 2,230 | 2,139 |
| Taxes paid related to net share settlement of restricted stock units | (3,059) | (5,933) | (18,065) |
| Net cash (used in) provided by financing activities | (29,606) | (4,535) | 185,642 |
| Effect of exchange rate changes on cash and cash equivalents | (112) | 23 | (303) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (7,660) | (258,253) | 213,757 |
| Cash, cash equivalents, and restricted cash at beginning of period | 90,443 | 348,696 | 134,939 |
| Cash, cash equivalents, and restricted cash at end of period | $82,783 | $90,443 | $348,696 |
| Supplemental disclosures of cash information | |||
| Cash paid for interest | $— | $8 | $1 |
| Cash paid for income taxes | $738 | $392 | $14 |
| Supplemental disclosures of cash flow information | |||
| Shares issued in lieu of payment | $216 | $319 | $296 |
| Operating lease right-of-use assets | $607 | $22,267 | $6,079 |
| Purchases of capital expenditures in accounts payable and accrued liabilities | $647 | $1,423 | $3,953 |
| Employee stock purchase plan shares included in accrued compensation | $556 | $686 | $1,521 |
| Contingent consideration | $3,499 | $— | $5,341 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.